Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Piper Sandler Upgrades Solid Biosciences to Overweight
Buy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic Partnerships
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy Bio (TSVT)
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics (SRPT) Gets a Hold From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Alcon (ALC) and Sarepta Therapeutics (SRPT)
Buy Rating Affirmed for Sarepta Therapeutics as Elevidys Shows Strong Sales and Promising Outlook
Sarepta Therapeutics Analyst Ratings
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Sarepta Therapeutics (SRPT) and AptarGroup (ATR)
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Immunocore Holdings (IMCR)
Sarepta Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Eli Lilly & Co (LLY) and Sarepta Therapeutics (SRPT)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF) and Sarepta Therapeutics (SRPT)
Sarepta Therapeutics' Stock Buy Rating Affirmed Amid Positive FDA Regulatory Milestones
Buy Rating Affirmed for Sarepta Therapeutics Amid Anticipated Elevidys Label Expansion and Market Growth Potential
Buy Rating for Sarepta Therapeutics on Regulatory Optimism and Strong Drug Prospects
Analysts Offer Insights on Healthcare Companies: Organon (OGN) and Sarepta Therapeutics (SRPT)
Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price Target
No Data